Table 2.
Population characteristics
| Patient characteristics | All patients (N = 2,272) | White patients (n = 867) | Black patients (n = 603) | p value |
|---|---|---|---|---|
| Age, mean (SD), year | 61.4 ± 14.1 | 62.8 ± 13.9 | 62.1 ± 13.1 | 0.2847 |
| Male, n (%) | 1,475 (64.9) | 579 (66.8) | 340 (56.4) | <0.001 |
| Self-reported ethnicity, no. (%) | ||||
| Hispanic/Latino | 588 (25.8) | 260 (30.0) | 13 (2.2) | <0.001 |
| Non-Hispanic/non-Latino | 1,368 (60.2) | 555 (64.0) | 551 (91.4) | |
| Not known | 298 (13.1) | 52 (5.9) | 13 (2.1) | |
| Self-reported race, no. (%) | ||||
| White | 867 (38.1) | Not applicable |
||
| Black | 601 (26.4) | |||
| Asian | 144 (6.3) | |||
| American Indian/Alaska Native | 11 (0.5) | |||
| Native Hawaiian/Other Pacific Islander | 15 (0.7) | |||
| More than one race | 28 (1.2) | |||
| Unknown/unspecified | 605 (26.6) | |||
| SOFA scores, mean ± SDa | ||||
| New York priority group | 1.4 ± 0.6 | 1.4 ± 0.5 | 1.6 ± 0.6 | <0.001 |
| Raw SOFA score | 6.9 ± 2.7 | 6.6 ± 2.4 | 7.1 ± 2.7 | <0.001 |
| Colorado priority group | 3.3 ± 1.2 | 3.3 ± 1.1 | 3.5 ± 1.2 | <0.001 |
| SOFA score componentsa, mean (SD)b | ||||
| Respiratory | 3.0 (0.99) | 2.96 (0.99) | 3.02 (1.00) | 0.2374 |
| Coagulation | 0.22 (0.54) | 0.24 (0.58) | 0.23 (0.54) | 0.6619 |
| Liver | 0.16 (0.48) | 0.14 (0.44) | 0.17 (0.54) | 0.3050 |
| Cardiovascular | 2.26 (1.54) | 2.28 (1.53) | 2.19 (1.57) | 0.3038 |
| Central nervous system | 0.30 (0.46) | 0.33 (0.47) | 0.31 (0.46) | 0.2251 |
| Renal | 0.95 (1.34) | 0.75 (1.21) | 1.44 (1.49) | <0.001 |
| Comorbidities, n (%)c | ||||
| Congestive heart failure | 204 (8.9) | 76 (8.8) | 83 (13.8) | 0.003 |
| Chronic pulmonary diseased | 489 (21.5) | 209 (24.1) | 158 (26.2) | 0.3942 |
| Chronic renal diseasee | 407 (17.9) | 120 (13.8) | 134 (22.2) | <0.001 |
| End-stage renal disease | 75 (3.3) | 26 (3.0) | 31 (5.1) | 0.051 |
| Active malignancy | 101 (4.4) | 58 (6.7) | 22 (3.7) | 0.015 |
| Diabetes with complications | 357 (15.7) | 109 (12.6) | 132 (21.9) | <0.001 |
| Chronic liver disease | 71 (3.1) | 28 (3.2) | 16 (2.7) | 0.6298 |
| Death, n (%) | 1,073 (47.2) | 407 (46.9) | 286 (47.5) | 0.8494 |
aSOFA score components are rated on a scale of 0–4. Table S2 provides definitions for each component used in this paper.
A total of 594 patients were excluded from the analysis if any of the components of the SOFA score were missing other than the cardiovascular component.
Table S2 provides for definitions of comorbidities and highlights differences in comorbidities between the full Colorado and the modified Colorado model used in this paper.
Chronic pulmonary disease as defined by chronic obstructive pulmonary disease or asthma.
Chronic renal disease as defined by chronic kidney disease (estimated glomerular filtration rate (eGFR) < 60 on at least 2 consecutive values at least 12 weeks apart) or end-stage renal disease.